Get the Stockscreener App
94.47
0.16%
-0.15
After Hours:
94.55
0.08
+0.08%
Globus Medical Inc stock is traded at $94.47, with a volume of 2.23M.
It is down -0.16% in the last 24 hours and up +6.84% over the past month.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
See More
Previous Close:
$94.62
Open:
$95.77
24h Volume:
2.23M
Relative Volume:
1.30
Market Cap:
$12.64B
Revenue:
$2.51B
Net Income/Loss:
$185.56M
P/E Ratio:
70.50
EPS:
1.34
Net Cash Flow:
$517.59M
1W Performance:
+8.21%
1M Performance:
+6.84%
6M Performance:
+64.84%
1Y Performance:
+9.15%
1-Day Range:
$91.52
$96.06
1-Week Range:
$87.00
$101.40
52-Week Range:
$51.79
$101.40
Globus Medical Inc Stock (GMED) Company Profile
Name
Globus Medical Inc
Sector
Industry
Phone
610-930-1800
Address
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
94.47 | 12.66B | 2.51B | 185.56M | 517.59M | 1.34 |
|
ABT
Abbott Laboratories
|
125.92 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.64 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.54 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.53 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-07-25 | Upgrade | Truist | Hold → Buy |
| Oct-28-25 | Resumed | Stifel | Hold |
| May-27-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-10-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-20-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-18-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-19-23 | Upgrade | Stifel | Hold → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-13-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-10-23 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-10-23 | Downgrade | Loop Capital | Buy → Hold |
| Feb-10-23 | Downgrade | Needham | Buy → Hold |
| Feb-10-23 | Downgrade | Truist | Buy → Hold |
| Feb-10-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-28-22 | Initiated | Wells Fargo | Overweight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-13-21 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-29-21 | Initiated | Loop Capital | Buy |
| Feb-18-21 | Resumed | Needham | Buy |
| Dec-08-20 | Initiated | Citigroup | Buy |
| Oct-20-20 | Initiated | Stifel | Hold |
| Aug-06-20 | Reiterated | Needham | Buy |
| Aug-06-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-21-20 | Initiated | Northland Capital | Market Perform |
| Jul-06-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-08-20 | Reiterated | Needham | Buy |
| Mar-18-20 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Aug-02-19 | Reiterated | Needham | Buy |
| May-24-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| May-03-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Upgrade | UBS | Neutral → Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-27-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-18 | Reiterated | Needham | Buy |
| Apr-04-18 | Upgrade | Needham | Hold → Buy |
View All
Globus Medical Inc Stock (GMED) Latest News
Why Globus Medical (GMED) Is Up 8.2% After Raising 2026 Revenue Guidance And Integration Outlook - simplywall.st
Stifel maintains GMED buy rating, $92 target amid NVRO buyout - MSN
Audubon’s Globus Medical Wins $9.5 Million Settlement - MSN
Should You Buy Globus Medical (GMED) After Golden Cross? - MSN
Globus Medical’s blockbuster finish sets a high-stakes 2026 showdown - MSN
Globus Medical’s Blockbuster Finish Sets a High-Stakes 2026 Showdown - MyChesCo
Retail Trends: Can Globus Medical Inc stock maintain growth trajectoryTrade Exit Report & Verified Chart Pattern Trade Signals - moha.gov.vn
Why Globus Medical (GMED) is a top growth stock for the long term - MSN
Globus Medical 2026 Outlook: Why M&A Math Mires The Valuation (NYSE:GMED) - Seeking Alpha
GMED: Canaccord Genuity Raises Price Target to $112 | GMED Stock News - GuruFocus
Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term - Yahoo Finance
Globus Medical stock price target raised to $112 by Canaccord on strong results - Investing.com Canada
Globus Medical Inc (NYSE:GMED): A GARP Stock with Strong Growth and a Reasonable Price - Chartmill
Is Globus Medical Inc. stock dividend yield sustainable2025 Trade Ideas & Long-Term Growth Stock Strategies - ulpravda.ru
Can Globus Medical Inc. stock maintain growth trajectoryTrade Exit Summary & Entry Point Confirmation Signals - ulpravda.ru
Why Globus Medical Inc. stock could benefit from AI revolution2025 Top Gainers & Community Shared Stock Ideas - ulpravda.ru
Will Globus Medical Inc. stock benefit from automationNew Guidance & Stock Portfolio Risk Control - ulpravda.ru
GMED insider (Form 144) plans sale of 3,594 common shares - Stock Titan
GMED (GMED) holder files to sell 2,000 shares after RSU vesting - Stock Titan
Globus Medical jumps 9% after upbeat revenue and earnings outlook - Yahoo Finance
Globus Medical (GMED) Price Target Raised to $115.00 by Piper Sa - GuruFocus
Globus Medical stock hits all-time high at 99.5 USD By Investing.com - Investing.com Canada
Globus Medical climbs on better-than-expected Q4, FY outlook - TradingView — Track All Markets
US-based Globus Medical anticipates 25.2% sales increase in Q4 2025 - Medical Buyer
Citizens reiterates Market Perform rating on Globus Medical stock By Investing.com - Investing.com Canada
Globus Medical (GMED) Surges on Strong Sales Projections - GuruFocus
Jon Najarian: Globus Medical shares surge 9 percent on strong Q4 sales projection - Traders Union
Jefferies raises Globus Medical stock price target to $115 on strong Q4 - Investing.com Canada
Why Globus Medical Stock Is Flying Higher in After-Hours Trading - The Globe and Mail
Globus Medical Surges On Preliminary Q4 And FY25 Sales Results; Issues FY26 Guidance - Nasdaq
Globus Medical Stock Pre-Market (+9.3%): Strong Prelim Q4 Sales & Upbeat 2026 Guidance - Trefis
Why Globus Medical stock is flying higher in after-hours trading - MSN
Globus Medical reports 25.2% revenue growth in Q4 2025 By Investing.com - Investing.com Canada
Globus Medical (GMED) Projects Strong Revenue Growth for 2025 - GuruFocus
GMED Sees Strong Q4 Results, Eyes Growth in 2026 - GuruFocus
Globus Medical Q4 Preliminary Sales Rise 25% From Year Earlier; Shares Jump After Hours - MarketScreener
GMED Stock Sees Significant Annual Growth - GuruFocus
GMED Raises Revenue Forecast for FY26 - GuruFocus
Globus Medical reports 25.2% revenue growth in Q4 2025 - Investing.com India
Globus Medical's preliminary Q4 sales beat estimates - TradingView — Track All Markets
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results - The Manila Times
Globus Medical (GMED) shares preliminary 2025 sales results and 2026 guidance - Stock Titan
Globus Medical Reports Strong Preliminary Sales Results for Q4 and Full Year 2025 - Quiver Quantitative
Globus posts record 2025 sales, sets 2026 revenue guidance up to $3.22B - Stock Titan
Stifel raises Globus Medical stock price target to $90 on strong outlook - Investing.com Canada
Will Globus Medical Inc. stock attract ESG investors2026 world cup usa national team qualification top scorers counter attacking winner prediction tactical review - ulpravda.ru
Globus Medical (GMED) director gifts 6,100 Class A shares, updates holdings - Stock Titan
Globus Medical Inc Shs A Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh A - TradingView — Track All Markets
Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock? - MSN
Does Globus Medical (NYSE:GMED) Deserve A Spot On Your Watchlist? - Yahoo Finance
Allspring Global Investments Holdings LLC Acquires 312,149 Shares of Globus Medical, Inc. $GMED - MarketBeat
Globus Medical Inc Stock (GMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):